Peter U. Park, Ph.d

Biography

  Peter Park, Ph.D., is vice president of oncology research at Bicycle Therapeutics, Inc. He brings over 14 years of oncology drug discovery experience in antibody and antibody-drug conjugate (ADC) therapeutics. Previously, Peter was vice president of biology at Mersana Therapeutics, Inc., where he co-invented and oversaw the discovery and development of novel Fleximer-based ADC, XMT-1522 and XMT-1536. He also led the joint research steering committee for the collaboration with Merck KgGA. Prior to that, Peter served at ImmunoGen, Inc., in various roles, most recently as senior director of discovery research. In this role, he managed the discovery research portfolio for the development of novel monoclonal antibody and ADCs for the internal pipeline and for partners. He oversaw three departments that included discovery research, antibody engineering and cell line development. At ImmunoGen, he co-invented and advanced many clinical candidates, including Isatuximab (SAR650984), which was licensed to Sanofi and is currently in Phase 3 testing for multiple myeloma. Peter received his B.S and Ph.D. in biology from the Massachusetts Institute of Technology.

Research Interest

Pharmaceutics, clinical sciences,biotechnology, biomedical, drug delivery, Health Sciences, Sustainability, testing and inspection , chemical, environmental solutions, biochemistry